Device Trial Radar · NCT05127551
Clinical Study of Glaukos® Trabecular Micro-Bypass System Model iS3 Infinite Vs. Competitor
Last checked: Nov 20, 2026Latest source record: Aug 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
179
Actual
Start
Nov 27, 2021
Primary completion
Feb 29, 2024
Study completion Feb 28, 2025
Sponsor
- Lead sponsor
- Glaukos CorporationPublic (GKOS)
- Sponsor type
- Industry
- First posted
- Nov 19, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 35 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study of the iStent Infinite product in the treatment of open-angle glaucoma vs competitor
Conditions
- Glaucoma
- Glaucoma, Open-Angle
Interventions
iStent InfiniteDevice
Implantation of the iStent Infinite
Competitor DeviceDevice
Implantation of competitor device
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Mean Diurnal Intraocular PressureTime frame: Month 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Glaukos Investigator Sites
Montreal, Qubec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.